Fennec (FENC) CEO acquires 1,159 shares as restrictions lift
Rhea-AI Filing Summary
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported acquiring 1,159 common shares through the exercise or conversion of a derivative award. A footnote explains these shares were released from restriction from shares awarded on 3/28/2025.
After this transaction, Hackman directly holds 61,666 common shares. The filing reflects a routine compensation-related release of previously granted equity rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Common Shares | 1,159 | $0.00 | -- |
Footnotes (1)
- [object Object]
Key Figures
Key Terms
Exercise or conversion of derivative security financial
FAQ
What did FENNEC (FENC) CEO Jeffrey Hackman report in this Form 4?
Jeffrey S. Hackman reported acquiring 1,159 Fennec common shares. The shares came from the exercise or conversion of a prior equity award, not from an open-market trade. This increased his directly held stake as reflected in the filing.
Was the FENNEC (FENC) CEO’s Form 4 transaction an open-market buy or sell?
The Form 4 does not show an open-market buy or sell. Instead, it records the acquisition of 1,159 common shares through exercise or conversion of a derivative award, tied to shares previously awarded and later released from restriction.
What does the footnote in Jeffrey Hackman’s FENNEC (FENC) Form 4 explain?
The footnote states the 1,159 shares represent shares released from restriction from shares awarded on 3/28/2025. This clarifies that the transaction reflects vesting or release of a prior equity grant rather than a new market purchase.
How large is the FENNEC (FENC) CEO’s latest equity award release?
The reported release covers 1,159 common shares. These shares stem from a previously granted award that became unrestricted, modestly increasing CEO Jeffrey S. Hackman’s directly held position as disclosed in the Form 4.